Supplemental material

Online Table 1: DATECAN Pancreatic cancer experts

Full Name SPECIALTY Institution City COUNTRY

Coordinating Committee (CC)

Bonnetain, F Methodology / Biostatistics

University Hospital of Besançon and GERCOR Besançon France

Collette L Methodology / Biostatistics

European Organization of Research and Treatment of Cancer Brussels Belgium

Dousseau A Methodology / Biostatistics

Institut Bergonié, Comprehensive Cancer Center Bordeaux France

Steering Committee (SC)

Bonsing B oncology Leiden University Medical Cente Leiden Netherlands

Conroy T Oncology Center Alexis Vautrin Comprehensive Cancer Center Nancy France

Glimelius B Radiation Oncology Uppsala University hospital Uppsala Sweden

Haustermans K Radiation Oncology University hospital Leuven Belgium

Lacaine L Surgery Tenon hospital Paris France

Van Laethem JL Medical Oncology Erasme Hospital Brussels Belgium

Rating Committee (RC)

Aparicio T Gastroenterology Avicenne hospital Bobigny France

Aust D pathology University Hospital Carl-Gustav-Carus Dresden Germany

Bassi C Surgical oncology Hospital of 'G.B.Rossi', University of Verona Verona Italy

Berger V Oncology and methodology

Centre Paul Papin, Comprehensive Cancer Center Angers France

Chamorey E Methodology / Biostatistics

Centre Antoine Lacassagne, Comprehensive Cancer Center Nice France

Chibaudel B Medical oncology Hôpital Saint-Antoine Paris France

Dahan L Gastroenterologys Hopital la Timone Marseille France

De Gramont E Medical oncology Hôpital Saint-Antoine Paris France

Delpero JR Surgical oncology Institut Paoli Calmette Comprehensive Cancer Center Marseille France

Dervenis C Surgery Agia Olga Hospital Athens Greece

Ducreux M Medical oncology Institut Gustave Roussy Comprehensive Cancer Center

Villejuif France

Gal J Statisticien Centre Antoine Lacassagne, Comprehensive Cancer Center Nice France

Gerber E Radiotherapy Institut fuer Radioonkologie Vienna Austria

Ghaneh P Surgery Royal Liverpool Hospital Liverpool UK

Hammel P gastroenterology Beaujon Hospital Paris France

Page | 1

Hendlisz A Medical oncology Jules Bordet Institute Brussels Belgium

Jooste, V Epidemiology Cancer Registry Dijon France

Labianca R Medical oncology Ospedali Riuniti di Bergamo Bergamo Italy

Latouche A StatisticsCentre for Research in Epidemiology and Population Health, Inserl U1018,

Villejuif France

Lutz M Gastroenterology Caritas Hospital Saarbrucken Germany

Macarulla T Medical oncology Vall d'Hebron University Hospital Barcelona Spain

Malka D Medical oncology Institut Gustave Roussy Comprehensive Cancer Center

Villejuif France

Mauer M biostatistics European Organization of Research and Treatment of Cancer Brussels Belgium

Mitry E Gastroenterology Institut Curie - Hôpital René Huguenin Saint Cloud France

Neoptolemos J Surgical oncology University of Liverpool and Royal Liverpool University Hospital Liverpool UK

Pessaux P Surgery university hospital Strasbourg France

Sauvanet A Surgery Beaujon Hospital Paris France

Tabernero J Medical oncology Vall d'Hebron University Hospital Barcelona Spain

Taieb J Gastroenterology Georges Pompidou European hospital Paris France

van Tienhoven Radiotherapy Academisch Medisch Centrum Amsterdam Netherlands

Peer-review committee

Carine Bellera

Biostatistics/Methodology

Institut Bergonié, Comprehensive Cancer Center and INSERM CIC-EC7, France

Bordeaux France

Simone Mathoulin-Pélissier

Institut Bergonié, Comprehensive Cancer Center and INSERM CIC-EC7, France

Bordeaux France

Sophie Gourgou Biostatistical Unit, Centre Val d’Aurelle, Comprehensive Cancer Centre, Montpellier, France

Montpellier France

Page | 2

Online table 2 Report of the 1st and 2nd round results of Cancer-specific survival

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 3

Online Table 3: Report of the 1st and 2nd round results of Disease Free Survival

In green: consensus for including eventIn pink: consensus for not including eventWhite, blue or grey: no consensus

Page | 4

Online Table 4: Report of the 1st and 2nd round results of Relapse Free Survival

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 5

Online Table 5: Report of the 1st and 2nd round results of Loco Regional Relapse Free Survival

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 6

Online Table 6: Report of the 1st and 2nd round results of time to local recurrence

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 7

Online Table 7: Report of the 1st and 2nd round results of Distant Metastasis Free Survival (DMFS)

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 8

Online Table 8: Report of the 1st and 2nd round results of Time to Treatment Failure (TTF)

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 9

Online Table 9: Report of the 1st and 2nd round results of Failure Free Survival (FFS)

In green: consensus for including eventIn pink: consensus for not including eventWhite, blue or grey: no consensus

Page | 10

Online Table 10: Report of the 1st and 2nd round results of Progression Free Survival (PFS)

In green: consensus for including eventIn pink: consensus for not including eventWhite, blue or grey: no consensus

Page | 11

Online Table 11 : Report of the 1st and 2nd round results of Time to Progression (TTP)

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 12

Online Table 12: Report of the 1st and 2nd round results of Time to Local Progression (TLP)

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 13

Online Table 13: Report of the 1st and 2nd round results of Metastatic Progression-free survival (MPFS)

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 14

Online Table 14: Report of the 1st and 2nd round results of time to performance status deterioration

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 15

Online Table 15: Report of the 1st and 2nd round results of time to Quality of life deterioration

In green: consensus for including eventIn pink: consensus for not including eventWhite or grey: no consensus

Page | 16